Aclarion Inc's stock surged by 25.39% in pre-market trading, reaching a 20-day high. This movement comes amid broader market weakness, with the Nasdaq-100 down 0.22% and the S&P 500 down 0.15%.
The surge is attributed to Aclarion's report of a 114% year-over-year growth in Nociscan scan volumes for Q4 2025, indicating rising market acceptance in chronic low back pain diagnosis. Additionally, the company has secured financial strength with $12 million in cash and no debt, extending its cash runway into 2027. This positive news reflects the company's ongoing commercial growth and strategic flexibility.
The implications of this growth are significant, as Aclarion aims to enhance its clinical validation and market penetration through the CLARITY trial, which is expected to generate high-quality clinical evidence. This positions the company favorably for future reimbursement discussions and long-term shareholder value.
Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.640
Low
23.00
Averages
23.00
High
23.00
Current: 3.640
Low
23.00
Averages
23.00
High
23.00
No data
About ACON
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
